Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1971 1
1974 1
1977 3
1979 2
1980 2
1981 3
1982 1
1984 2
1985 1
1986 5
1987 2
1988 1
1989 2
1990 3
1991 3
1992 4
1993 2
1994 3
1995 6
1996 7
1997 9
1998 13
1999 7
2000 16
2001 14
2002 11
2003 15
2004 16
2005 21
2006 31
2007 21
2008 28
2009 23
2010 27
2011 30
2012 43
2013 47
2014 45
2015 39
2016 34
2017 20
2018 32
2019 25
2020 40
2021 66
2022 80
2023 81
2024 130
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

919 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL. Budde LE, et al. Among authors: kwan a. Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5. Lancet Oncol. 2022. PMID: 35803286 Clinical Trial.
The neural basis of psychedelic action.
Kwan AC, Olson DE, Preller KH, Roth BL. Kwan AC, et al. Nat Neurosci. 2022 Nov;25(11):1407-1419. doi: 10.1038/s41593-022-01177-4. Epub 2022 Oct 24. Nat Neurosci. 2022. PMID: 36280799 Free PMC article. Review.
Psychotropic Drug-Related Weight Gain and Its Treatment.
McIntyre RS, Kwan ATH, Rosenblat JD, Teopiz KM, Mansur RB. McIntyre RS, et al. Among authors: kwan ath. Am J Psychiatry. 2024 Jan 1;181(1):26-38. doi: 10.1176/appi.ajp.20230922. Am J Psychiatry. 2024. PMID: 38161305 Review.
Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.
McIntyre RS, Phan L, Kwan ATH, Mansur RB, Rosenblat JD, Guo Z, Le GH, Lui LMW, Teopiz KM, Ceban F, Lee Y, Bailey J, Ramachandra R, Di Vincenzo J, Badulescu S, Gill H, Drzadzewski P, Subramaniapillai M. McIntyre RS, et al. Among authors: kwan ath. Brain. 2024 Mar 1;147(3):849-857. doi: 10.1093/brain/awad377. Brain. 2024. PMID: 37936330 Clinical Trial.
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL. Budde LE, et al. Among authors: kwan a. J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16. J Clin Oncol. 2022. PMID: 34914545 Free PMC article. Clinical Trial.
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
Matasar M, Bartlett NL, Shadman M, Budde LE, Flinn I, Gregory GP, Kim WS, Hess G, El-Sharkawi D, Diefenbach CS, Huang H, To I, Parreira J, Wu M, Kwan A, Assouline S. Matasar M, et al. Among authors: kwan a. Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):240-253. doi: 10.1016/j.clml.2023.12.005. Epub 2023 Dec 12. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38195322 Free article. Clinical Trial.
919 results